Hacer Karatas, Ph.D. - Publications

Affiliations: 
2012 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Nanoscale analytical techniques, chemical separations, mass spectrometry, microfluidics, neurochemistry, and islet biology

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Karatas H, Li Y, Liu L, Ji J, Lee S, Chen Y, Yang J, Huang L, Bernard D, Xu J, Townsend EC, Cao F, Ran X, Li X, Wen B, et al. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. Journal of Medicinal Chemistry. PMID 28603984 DOI: 10.1021/acs.jmedchem.6b01796  0.56
2016 Liu L, Lei I, Karatas H, Li Y, Wang L, Gnatovskiy L, Dou Y, Wang S, Qian L, Wang Z. Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts. Cell Discovery. 2: 16036. PMID 27924221 DOI: 10.1038/celldisc.2016.36  0.56
2016 Xu J, Li L, Xiong J, denDekker A, Ye A, Karatas H, Liu L, Wang H, Qin ZS, Wang S, Dou Y. MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Cell Discovery. 2: 16008. PMID 27462455 DOI: 10.1038/celldisc.2016.8  0.56
2016 Zhang H, Gayen S, Xiong J, Zhou B, Shanmugam AK, Sun Y, Karatas H, Liu L, Rao RC, Wang S, Nesvizhskii AI, Kalantry S, Dou Y. MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency. Cell Stem Cell. PMID 26996599 DOI: 10.1016/j.stem.2016.02.004  0.56
2015 Karatas H, Lee SY, Townsend EC, Cao F, Xu J, Bernard D, Liu L, Dou Y, Wang S. Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 protein-protein interaction as inhibitors of the MLL1 methyltransferase activity Chinese Chemical Letters. 26: 455-458. DOI: 10.1016/j.cclet.2015.03.030  0.56
2014 Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, Hess JL, Atadja P, Lei M, Qin ZS, Malek S, et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Molecular Cell. 53: 247-61. PMID 24389101 DOI: 10.1016/j.molcel.2013.12.001  0.56
2013 Zhou H, Liu L, Huang J, Bernard D, Karatas H, Navarro A, Lei M, Wang S. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. Journal of Medicinal Chemistry. 56: 1113-23. PMID 23244744 DOI: 10.1021/jm3015298  0.56
2013 Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. Journal of the American Chemical Society. 135: 669-82. PMID 23210835 DOI: 10.1021/ja306028q  0.56
2010 Karatas H, Townsend EC, Bernard D, Dou Y, Wang S. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. Journal of Medicinal Chemistry. 53: 5179-85. PMID 20575550 DOI: 10.1021/jm100139b  0.56
Show low-probability matches.